Drugs / VGX-3400
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01184976 | Aug 2010 → Apr 2012 | — | GeneOne Life Science, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGX-3400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01184976 ↗ |
| Modality | Vaccine | “a DNA plasmid vaccine for HS Avian Influenza (VGX-3400)” NCT01184976 ↗ |
| Route | Intramuscular | “administered via IM injection + electroporation” NCT01184976 ↗ |